Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivetta Danylesko

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Current Treatment Options in Oncology|February 10, 2018
Second Malignancies after Hematopoietic Stem Cell TransplantationIvetta Danylesko, Avichai Shimoni
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2013
Allogeneic stem cell transplantation and targeted immunotherapy for multiple myelomaIvetta Danylesko, Avichai Shimoni, Arnon Nagler
Clinical & Developmental Immunology|June 1, 2012
Novel strategies for immunotherapy in multiple myeloma: previous experience and future directionsIvetta Danylesko, Katia Beider, Avichai Shimoni, et al.
Immunotherapy|October 11, 2012
Monoclonal antibody-based immunotherapy for multiple myelomaIvetta Danylesko, Katia Beider, Avichai Shimoni, et al.
Bone Marrow Transplantation|September 3, 2020
Carfilzomib combined with cyclosporine and methotrexate for the prevention of graft-versus-host disease after allogeneic stem-cell transplantation from unrelated donorsAvichai Shimoni, Noga Shem-Tov, Ronit Yerushalmi, et al.
Rapid Communications in Mass Spectrometry : RCM|June 27, 2019
A simplified method for detection of N-terminal valine adducts in patients receiving treosulfanGunnar Boysen, Avichai Shimoni, Ivetta Danylesko, et al.
American Journal of Hematology|January 5, 2017
The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donorsRonit Yerushalmi, Noga Shem-Tov, Ivetta Danylesko, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 12, 2017
Isolated Extramedullary Relapse of Acute Leukemia after Allogeneic Stem Cell Transplantation: Different Kinetics and Better Prognosis than Systemic RelapseNoga Shem-Tov, Francesco Saraceni, Ivetta Danylesko, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 8, 2015
Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic SyndromesIvetta Danylesko, Rina Sareli, Nira Bloom-Varda, et al.
Acta Haematologica|August 26, 2015
Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot StudyIvetta Danylesko, Rina Sareli, Nira Varda-Bloom, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Current Treatment Options in Oncology|February 10, 2018
Second Malignancies after Hematopoietic Stem Cell TransplantationIvetta Danylesko, Avichai Shimoni
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2013
Allogeneic stem cell transplantation and targeted immunotherapy for multiple myelomaIvetta Danylesko, Avichai Shimoni, Arnon Nagler
Clinical & Developmental Immunology|June 1, 2012
Novel strategies for immunotherapy in multiple myeloma: previous experience and future directionsIvetta Danylesko, Katia Beider, Avichai Shimoni, et al.
Immunotherapy|October 11, 2012
Monoclonal antibody-based immunotherapy for multiple myelomaIvetta Danylesko, Katia Beider, Avichai Shimoni, et al.
Bone Marrow Transplantation|September 3, 2020
Carfilzomib combined with cyclosporine and methotrexate for the prevention of graft-versus-host disease after allogeneic stem-cell transplantation from unrelated donorsAvichai Shimoni, Noga Shem-Tov, Ronit Yerushalmi, et al.
Rapid Communications in Mass Spectrometry : RCM|June 27, 2019
A simplified method for detection of N-terminal valine adducts in patients receiving treosulfanGunnar Boysen, Avichai Shimoni, Ivetta Danylesko, et al.
American Journal of Hematology|January 5, 2017
The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donorsRonit Yerushalmi, Noga Shem-Tov, Ivetta Danylesko, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 12, 2017
Isolated Extramedullary Relapse of Acute Leukemia after Allogeneic Stem Cell Transplantation: Different Kinetics and Better Prognosis than Systemic RelapseNoga Shem-Tov, Francesco Saraceni, Ivetta Danylesko, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 8, 2015
Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic SyndromesIvetta Danylesko, Rina Sareli, Nira Bloom-Varda, et al.
Acta Haematologica|August 26, 2015
Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot StudyIvetta Danylesko, Rina Sareli, Nira Varda-Bloom, et al.
Pageof 5